← Back to Clinical Trials
Recruiting Phase 4 NCT06366412

Dexmedetomidine on Postoperative Cognitive Dysfunction and Serum Tau-217 Protein.

Trial Parameters

Condition Cognitive Impairment
Sponsor Minia University Hospital
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 94
Sex ALL
Min Age 65 Years
Max Age N/A
Start Date 2024-04
Completion 2025-03
Interventions
Dexmedetomidine Hydrochloridenormal saline

Brief Summary

To assess the effect of Dexmedetomidine on serum Tau-217 protein and its relation to the incidence and severity of postoperative cognitive dysfunction in elderly patients undergoing major surgery under general anesthesia.

Eligibility Criteria

Inclusion Criteria: * Patients aged \> 65 years old, both genders, Basal Metabolic Index range 18.5 to less than 35 American Society of Anesthesiologists I - III with Glasgow Coma Scale 14-15 undergoing major surgery under general anesthesia. Exclusion Criteria: * Patients will be excluded if they refused the enrollment in our study, Glasgow Coma Scale\<14 or if there is severe cardiac, liver or renal disease, patients have Alzehimer's Disease or any of the psychotic diseases, poorly educated patients and if there is any sensitivity to given drugs

Related Trials